Developing novel vaccines to cure HIV infection

Read more
HTI immunogen: a new therapeutic vaccine against HIV
Approach

HTI immunogen: a new therapeutic vaccine against HIV

The HTI immunogen was discovered by Dr. Christian Brander, CSO of AELIX Therapeutics, and co-workers. It is based on the observation that T-cell responses to certain HIV regions are enriched in individuals with enhanced control of their HIV-infection. The HTI immunogen brings these beneficial regions together as a vaccine immunogen…

More
WHO WE ARE

Meet the team

AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.

More

Whats new?

November 18, 2022

Exclusive VaccineNation interview with AELIX’s CSO, Dr. Christian Brander, on the development of HIV therapies

Read more

November 2, 2022

Positive results from AELIX’ HIV therapeutic vaccine clinical study AELIX-002 published in Nature Medicine

Read more

July 14, 2022

AELIX Therapeutics is supporting Fundació “La Caixa”’s project Alliance for Child Vaccination

Read more
More

Testimonials